By using our site you accept the terms of our cookie policy

Search

MMS Holdings: Most Outstanding Global CRO 2019

April 2, 2019

Image

MMS  Executive Leadership Team 

MMS Holdings is an award-winning, data-focused contract research organization (CRO) that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. As part of our overview of this year’s Biotechnology Awards we profile the firm to find out more and explore the secrets behind its phenomenal success.

 

Originally established as a data-focused CRO, MMS has maintained its core vision and their values since it’s inception.


In its learning management system, MMS has more than 750 trainings that were developed in house. In the past five years, the company has submitted more than 50 brand new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA). The company has offices and colleagues spanning four continents, with more than 600 full-time colleagues and technical specialists

.
This started with one woman, Dr. Uma Sharma. Thirteen years ago, what started as a small, oneperson venture has now grown to be a company that’s sized like it has been around for 50 years. Her positivity, visionary leadership, and philosophy on life form the narrative as to why the company has been so successful.


Based in Canton, Michigan, which is halfway between the emerging tech hubs of Ann Arbor and Detroit, MMS has used its strategic location to ensure its success from the beginning. When Pfizer closed their doors in Ann Arbor in 2006, Dr. Sharma went from a clinical lead to a consultant, supporting projects for various clients as an individual contributor. She was then quickly approached by former team members enquiring how they could support her efforts, wanting to work for her again. The timing was flawless, and slowly the new team grew.


Since then, MMS has grown into a global powerhouse with hundreds of colleagues across North America, Europe, India, and South Africa, using only organic methods. Today, she uses an entrepreneurial mindset to encourage every colleague to “pay it forward” and help the team grow across sites and continents. The closure of the Pfizer site was motivation, and it did not deter her from moving forward doing what she loves – helping to bring life changing therapies to patients worldwide.

Image

Health Analystics Collective Leadership Team 

Working alongside a wide range of clients, MMS now draws on a decade plus experience of various global colleagues to support leading pharmaceutical and biotech companies as well as many smaller enterprises across our
spectrum of services. A retention rate of greater than 93 percent globally allows for continuity in expertise and efficiency.
Having completed more than 50 submissions for drug approval over the last five years, the firm remains a top choice for sponsors who are looking for innovation and demand high quality from their CRO partners.


Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards.


Over the years, the firm has embraced regulatory changes globally and invested in colleague training and technology to better support sponsors as our industry evolves. MMS has been a pioneer in several key services, forging the way in Policy 0070 and other key transparency initiatives, leadership within organizations such as PhUSE, and their plain lay summary programs.


Since the beginning, MMS has established and maintained international quality certifications across all sites, allowing us to become leaders as a data CRO. With new regulations in effect, such as the GDPR, MMS easily

“This started with one woman, Dr. Uma Sharma. Thirteen years ago, what started as a small, one-person venture has now grown to be a company that’s sized like it has been around for 50 years. Her positivity, visionary leadership, and philosophy on life form the narrative as to why the company has been so successful.”

Image

adapts to bring many of its clients the required expertise, drawing on its efforts for well over a decade in the quality and information security space.


With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards. Operating internationally and supporting a range of clients and service users in such an important market, MMS works hard to remain at the forefront of emerging market developments to ensure excellence at all times.


The Regulatory Operations and Compliance Department at MMS completes an extensive, ongoing monthly review of all health authority websites in addition to actively reviewing real-time notifications of regulatory content updates. Once a month, all updated and/or new regulatory content, including guidelines and guidance for industry, is reviewed for relevance. If found pertinent, these updates are then distributed to colleagues within each of the departments for review. The Regulatory and Medical Writing and Safety Risk Management departments at MMS rely on the Technical Requirements Review Committee to analyze and evaluate the applicability and impact of the latest regulations and requirements on the work the firm undertakes.


This approach ensures that the firm is able to offer cutting-edge solutions and support. As a result, MMS has embraced regulatory changes globally and invested in colleague training and technology to better support sponsors as its industry evolves. The company has been a pioneer in several key services, forging the way in Policy 0070 and other key transparency initiatives, leadership within organizations such as PhUSE, and plain lay summary programs.


Seeking to build upon its current success, recently MMS partnered with the Julia Lab at MIT, Julia Computing, and the Center for
Translational Medicine (CTM) at the University of Maryland School of Pharmacy, to develop the Health Analytics Collective. The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science

Image

Sharma Uma 

Contact Us

+44 (0) 203 725 6847